NCT01548521View on ClinicalTrials.gov

Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

April 30, 2012

Conditions
Prader-Willi Syndrome
Interventions
DRUG

Oxytocin

2 ui intranasal administration for the 3 first patients, 4UI for the 3 following patients.

Trial Locations (1)

31059

Children Hospital of Toulouse Purpan, Toulouse

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER

NCT01548521 - Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies | Biotech Hunter | Biotech Hunter